Evidence map›Paper›PMID 39440714›Full record

ArticleFuture oncology (London, England)2024

Rates of febrile neutropenia and its causes in the real world.

Maxime Borgeaud, Simona Perano, Alfredo Addeo, Petros Tsantoulis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maxime BorgeaudDepartment of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland.ORCID 0000-0003-1262-5641
Simona PeranoDepartment of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland.
Alfredo AddeoDepartment of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland.
Petros TsantoulisDepartment of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Febrile NeutropeniaNeoplasmsAdultAgedAged, 80 and overAntineoplastic AgentsChemotherapy-Induced Febrile NeutropeniaFemaleGranulocyte Colony-Stimulating FactorHospitalizationHospital MortalityHumansMaleMiddle AgedRetrospective StudiesRisk FactorsAntineoplastic AgentsGranulocyte Colony-Stimulating Factordrug interactionsfebrile neutropeniagranulocyte-colony stimulating factorreal-world data

Identifiers

PMID39440714
PMCPMC11509001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.